The UK just made non-animal evidence planning more real: MHRA’s new advance Module 4 review route gives teams an earlier read on whether their package will hold up.
https://www.mattheneus.com/editorial/mhra-non-animal-methods-module-4-advance-review-guidance-2026-04-02 #HTA #RegulatoryAffairs #Pharma
Medicines and Healthcare products Regulatory Agency (MHRA) opens an advance Module 4 review route for medicines developed without animal studies
Medicines and Healthcare products Regulatory Agency (MHRA) now offers a clearer regulatory route for medicines developed without animal studies, including an advance Module 4 review mechanism by end-2026 and sharper expectations for how teams justify safety, mechanism, and evidence use in health technology assessment (HTA) and regulatory planning.
HTA submissions keep breaking where comparative evidence meets the economic model. If the lineage is not traceable, cost-effectiveness and budget-impact claims turn fragile fast.
https://www.mattheneus.com/editorial/hta-submissions-comparative-evidence-economic-model-lineage-problem-2026-04-02 #HTA #HealthEconomics #RegulatoryAffairs
Health technology assessment submissions now face a comparative-evidence to economic-model lineage problem
Health technology assessment (HTA) teams increasingly need cost-effectiveness and budget-impact outputs that remain directly traceable to the comparative evidence behind them. This article examines why broken lineage between analysis and modelling has become a submission risk and how AbangeLabs HTA Studio addresses that integration problem through verified current capabilities.
Eastern Europe and Central Asia need a health technology assessment (HTA) capacity-building playbook, not one-off pilots
A 30 March 2026 International Journal of Technology Assessment in Health Care review shows that Eastern Europe and Central Asia are moving toward broader health technology assessment (HTA) use, but uneven staffing, training, and governance mean evidence teams need reusable cross-market comparative and economic packages rather than one-off country submissions.
Four placebo-controlled trials showing no benefit is exactly the kind of evidence reset that changes payer and regulator narratives fast.
https://www.mattheneus.com/editorial/ema-tecovirimat-siga-mpox-restriction-four-rcts-no-benefit-2026-03-26 #HTA #RegulatoryAffairs #Pharma
European Medicines Agency moves to remove mpox use from Tecovirimat SIGA
The European Medicines Agency has recommended ending the mpox indication for Tecovirimat SIGA after four randomised placebo-controlled studies failed to show faster lesion resolution, pain relief or virologic benefit. The decision is a sharp reminder that early animal-model rationale does not survive reimbursement and regulatory scrutiny once human comparative data arrive.
NICE’s fezolinetant decision is a live case study in how reimbursement can clear despite uncertain indirect evidence beyond placebo. The real lesson is comparator-bridge discipline, not false certainty.
https://www.mattheneus.com/editorial/nice-fezolinetant-menopause-final-guidance-indirect-comparison-uncertainty-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis #RegulatoryAffairs
National Institute for Health and Care Excellence (NICE) clears fezolinetant when hormone replacement therapy is unsuitable
On 31 March 2026, the National Institute for Health and Care Excellence (NICE) published final guidance TA1143 recommending fezolinetant for moderate to severe vasomotor symptoms associated with menopause when hormone replacement therapy is unsuitable.
RWE fails when it is treated as a late appendix instead of submission architecture. Canada and EU HTA now reward early evidence planning and traceable decision logic.
https://www.mattheneus.com/editorial/rwe-submission-architecture-canada-eu-hta-evidence-planning-playbook-2026-04-01 #HTA #RWE #RegulatoryAffairs #EvidenceSynthesis
Real-world evidence (RWE) is now a submission architecture problem for health technology assessment (HTA) teams, not a late appendix
A new Value in Health Regional Issues environmental scan published online on 31 March 2026 found that 25.5% of Canada's Drug Agency reimbursement submissions from 2020 to mid-2024 already included real-world evidence (RWE), yet reviewers repeatedly challenged data quality, generalisability, and the lack of Canadian data.
When two NMAs disagree, the ranking usually isn’t the truth—it’s the output of study selection, population splits, and consistency choices. This playbook shows how to stress-test the decision question before a league table enters a dossier.
https://www.mattheneus.com/editorial/when-two-nmas-disagree-similarity-consistency-governance-playbook-2026-04-01 #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs
When two network meta-analyses disagree: a playbook for similarity, consistency, and ranking discipline
A new commentary in the Journal of the European Academy of Dermatology and Venereology uses two recent hidradenitis suppurativa network meta-analyses as a warning against overinterpreting treatment rankings. For HTA, market access, and evidence teams, the operational lesson is clear: lock the decision question first, document similarity and inconsistency checks explicitly, and show how network design choices change the answer before a ranking enters a dossier.
PBAC broadens blinatumomab PBS pathway in Ph-positive precursor B-cell ALL with D-ALBA lineage signal
PBAC recommended PBS listing amendments for blinatumomab in newly diagnosed Ph-positive precursor B-cell acute lymphoblastic leukaemia, citing single-arm Phase 2 D-ALBA evidence and implementation-focused restriction updates.
NICE EQ-5D-5L value set move resets cost-effectiveness governance for 2026 submissions
NICE's 25 March 2026 methods blog confirms a transition toward the newer EQ-5D-5L value set, with a formal implementation consultation expected in April through the modular update pathway. For market access and evidence teams, this is a near-term trigger to re-baseline health utility assumptions before finalising cost-effectiveness and budget impact narratives.
MHRA supply-chain cyber security push raises the bar for evidence operations resilience
MHRA published supply-chain cyber security guidance on 26 February 2026, inviting suppliers to complete Risk Ledger security profiles. For evidence teams, this elevates vendor-risk governance from IT hygiene to a regulatory-readiness priority tied to submission continuity and data integrity.
AbangeLabs